D-Penicillamine is used for patients with primary biliary cirrhosis due to its ability to decrease hepatic copper and modulate the immune response.
The results on effects of D-penicillamine in randomized-clinical trials of primary biliary cirrhosis patients are inconsistent.
Dr Gong and colleagues from Denmark systematically evaluated the benefits and harms of D-penicillamine for primary biliary cirrhosis.
The research team performed a systematic review with meta-analyses of randomized-clinical trials.
|D-Penicillamine decreased serum alanine aminotransferase activity|
|Alimentary Pharmacology & Therapeutics|
The team's primary outcomes were mortality, and mortality or liver transplantation.
The research team analyzed the data by fixed-effect and random-effect models.
The researchers identified 7 randomized trials including 706 patients.
D-Penicillamine was without significant effects on mortality, mortality or liver transplantation, or pruritus.
The team observed no significant effects on liver complications, progression of liver histological stage and liver biochemical variables.
D-Penicillamine significantly decreased serum alanine aminotransferase activity.
The researchers found that it led to significantly more adverse events.
Dr Gong's team concludes, “D-Penicillamine did not appear to reduce the risk of mortality or morbidity, and led to more adverse events in patients with primary biliary cirrhosis.”